UDRIK

This brand name is authorized in Germany, Lithuania

Active ingredients

The drug UDRIK contains one active pharmaceutical ingredient (API):

1 Trandolapril
UNII 1T0N3G9CRC - TRANDOLAPRIL

Trandolapril is a prodrug, which is rapidly, non-specifically hydrolysed to its potent, long-acting active metabolite, trandolaprilat (other metabolites are inactive) and acts as an orally-active angiotensin converting enzyme inhibitor (ACE inhibitor) without a sulphydryl group. In addition to inhibition of plasma ACE, trandolapril has been experimentally shown to inhibit tissue ACE (particularly vascular, cardial and adrenal). The clinical relevance of tissue ACE inhibition has not been established in humans.

Read about Trandolapril

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C09AA10 Trandolapril C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 00450967, 04660242, 04660288
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1092953

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.